Inhibitors of cyclin-dependent kinase 7 and uses thereof

US12281126B2 · kind B2 · utility

Assignee

• DANA-FARBER CANCER INSTITUTE, INC. · US

Inventors

• Nathanael S. Gray · Boston, US
• Tinghu Zhang · Brookline, US
• Nicholas Paul Kwiatkowski · Brookline, US
• Jie Jiang · Atlanta, US
• Mingfeng Hao · Hefei, CN
• Zhixiang He · Brookline, US

Key dates

• Filing date: Dec 27, 2019
• Grant date: Apr 22, 2025
• Expiry date: Jul 28, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds of the present disclosure are inhibitors of kinases (e.g., a cyclin-dependent kinase (CDK) (e.g., CDK7)). The compounds may be selective for inhibiting the activity of a kinase (e.g., CDK7) over certain other kinases (e.g., CDK2, CDK9, CDK12). Also provided are pharmaceutical compositions, kits, methods of use, and uses that involve the compounds. The compounds may be useful in inhibiting the activity of a kinase, down-regulating the transcription of MYC or MCL-1, inhibiting the growth of a cell, inducing apoptosis of a cell, treating a disease, and/or preventing a disease (e.g., proliferative disease, cystic fibrosis).